Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference
Senti Biosciences (Nasdaq: SNTI) announced that CEO Timothy Lu will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, 3:10–3:40 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Senti Biosciences (Nasdaq: SNTI) announced that CEO Timothy Lu will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, 3:10–3:40 PM ET. The presentation will cover the Gene Circuit platform, pipeline progress, and partnership opportunities. Live audio and video webcasts will be available on the company website.
Details
News Market Reaction – SNTI
On Feb 24, the day this news came out, SNTI closed 7.08% above the previous close.
Data tracked by StockTitan Argus for the Feb 24 session.
Key Figures
- Net loss
- $18.1M
- Q3 2025 net loss per 10‑Q
- Net loss (9M)
- $47.0M
- Nine months ended Sep 30, 2025
- Cash & equivalents
- $12.2M
- Balance at Sep 30, 2025
- Net cash used in ops
- $36.6M
- Nine months ended Sep 30, 2025
- GeneFab past-due rent
- $4.7M
- Past‑due sublease rent owed at quarter‑end
- Unpaid Alameda rent
- ~$0.4M
- Amount tied to default notice on Alameda lease
- CIRM grants
- $7.4M
- CIRM grant receipts to date for SENTI‑202
- Celadon ownership
- 45%
- Beneficial stake including warrant shares per Schedule 13D/A
Historical Context
-
Participation in Cell & Gene Live event showcasing Gene Circuit platform.
-
Completion of Phase 1 SENTI‑202 enrollment with favorable ASH 2025 data.
-
Selection for on‑stage presentation at Healthcare Conference Taipei 2026.
-
Virtual CEO Connect segment on AML data and RMAT designation.
-
CEO panel at Biotech Showcase 2026 on advances in cell and gene therapies.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
gene circuit technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will highlight the Company’s Gene Circuit technology platform, pipeline progress and strategic priorities, with an emphasis on opportunities for partnership across investment, research and development, manufacturing and clinical collaboration at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, from 3:10 – 3:40 PM ET.
Live audio of the webcast will be available on the Events page of the Investors section of the Company’s website (sentibio.com).
Interested parties may access the live video webcast here.
About Senti Bio
Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline comprises cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.
Availability of Other Information About Senti Biosciences, Inc.
For more information, please visit the Senti Bio website at www.sentibio.com or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
SNTI@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.